https://www.selleckchem.com/pr....oducts/Aloxistatin.h
246, 95%CI 1.278-8.243, p=0.013). At baseline, 48.8% and 28.8% had steatosis and severe steatosis, respectively. 4.2% had F3/F4 at baseline, which increased to 8.7% at 3 years. The rate of liver fibrosis progression in patients with persistent severe steatosis was higher than those without steatosis (41.3% vs. 23%, p=0.05). Persistent severe hepatic steatosis was independently associated with fibrosis progression (odds ratio 2.379, 95%CI 1.231-4.597, p=0.01). Conclusions CAP measurements have predictive values in virologically quies
Like
Comment
Share
